Comparison of antibacterial activities of meropenem and six other antimicrobials against Pseudomonas aeruginosa isolates from North American studies and clinical trials

Clinical Infectious Diseases

Volumn 24, Issue SUPPL. 2, 1997, Pages

  Iaconis, Joseph P ^a   Pitkin, Donald H ^b   Sheikh, Waheed ^b   Nadler, Harriette L ^b  

^a ASTRAZENECA   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAMASE; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; MEROPENEM; OUTER MEMBRANE PROTEIN; PIPERACILLIN; PORIN; TOBRAMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; CONTROLLED STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NORTH AMERICA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

EID: 0030891832     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/24.supplement_2.s191     Document Type: Article

References (19)

1. Craven DE, Steger KA, Barber TW. Preventing nosocomial pneumonia: state of the art and perspectives for the 1990's. Am J Med 1991;91(suppl 3B):44S-53S.
2. Emori TG, Banerjee SN, Culver DH, et al. Nosocomial infections in elderly patients in the United States, 1986-1990. Am J Med 1991;91(suppl 3B):289S-93S.
3. Shaberg DR, Culver DU, Gaynes RP. Major trends in the microbial etiology of nosocomial infection. Am J Med 1991;91(suppl 3B):72S-5S.
4. Moellering RC Jr, Eliopoulos GM, Sentochik DE. The carbapenems: new broad spectrum β-lactam antibiotics. J Antimicrob Chemother 1989; 24(suppl A):1-7.
5. Calandra G, Ricci F, Wang C, Brown K. Cross-resistance and imipenem [letter]. Lancet 1986;2:340-1.
6. Margaret BS, Drusano GL, Standiford HC. Emergence of resistance to carbapenem antibiotics in Pseudomonas aeruginosa. J Antimicrob Chemother 1989;24(suppl A): 161-7.
7. Vurma-Rapp U, Kayser FH, Hadorn K, Wiederkehr F. Mechanism of imipenem resistance acquired by three Pseudomonas aeruginosa strains during imipenem therapy. Eur J Clin Microbiol Infect Dis 1990; 9: 580-7.
8. Livermore DM. Interplay of impermeability and chromosomal β-lactamase activity in imipenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 1992;36:2046-8.
9. Satake S, Yoshihara E, Nakae T. Diffusion of β-lactam antibiotics through liposome membranes reconstituted from purified porins of the outer membrane of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1990; 34:685-90.
10. Edwards JR. Meropenem: a microbiological overview. J Antimicrob Chemother 1995;36(suppl A):1-17.
11. Iaconis J, Nadler H, Skinner M, Tabinowski A, Sheikh W. Rapid bioassay screen for detection of metallo-β-lactamases from selected bacteria [abstract no 951]. In: Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 1991:257.
12. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. NCCLS document M7-A3. Villanova, Pennsylvania: National Committee for Clinical Laboratory Standards, 1993.
13. Clarke AM, Zemcov SJV. In-vitro activity of meropenem against clinical isolates obtained in Canada. J Antimicrob Chemother 1989;24(suppl A):47-55.
14. Jones RN, Aldridge KE, Allen SD, et al. Multicenter in vitro evaluation of SM-7338, a new carbapenem. Antimicrob Agents Chemother 1989; 33:562-5.
15. Neu HC, Novelli A, Chin N-X. In vitro activity and β-lactamase stability of a new carbapenem, SM-7338. Antimicrob Agents Chemother 1989; 33:1009-18.
16. Sanders CC, Sanders WE, Thomson KS, Iaconis JP. Meropenem: activity against resistant Gram-negative bacteria and interactions with β-lactamases. J Antimicrob Chemother 1989;24(suppl A):187-96.
17. Inderlaid CB, Lancero MG, Young LS. Bacteriostatic and bactericidal in-vitro activity of meropenem against clinical isolates, including Mycobacterium avium complex. J Antimicrob Chemother 1989;24(suppl A): 85-99.
18. Sentochnik DE, Eliopoulous GM, Ferraro MJ, Mollering RC Jr. Comparative in vitro activity of SM7338, a new carbapenem antimicrobial agent. Antimicrob Agents Chemother 1989;33:1232-6.
19. Jorgensen JH, Maher LA, Howell AW. Activity of meropenem against antibiotic-resistant or infrequently encountered gram-negative bacilli. Antimicrob Agents Chemother 1991;35:2410-14.